These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 38658642)

  • 1. Predicting FFAR4 agonists using structure-based machine learning approach based on molecular fingerprints.
    Sherwani ZA; Tariq SS; Mushtaq M; Siddiqui AR; Nur-E-Alam M; Ahmed A; Ul-Haq Z
    Sci Rep; 2024 Apr; 14(1):9398. PubMed ID: 38658642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A high-throughput structural dynamics approach for identification of potential agonists of FFAR4 for type 2 diabetes mellitus therapy.
    Jhinjharia D; Kaushik AC; Sahi S
    J Biomol Struct Dyn; 2023 Nov; ():1-21. PubMed ID: 37978906
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of Selective Novel Hits against
    Nyamai DW; Tastan Bishop Ö
    Int J Mol Sci; 2020 May; 21(11):. PubMed ID: 32471245
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The molecular mechanism of phytosphingosine binding to FFAR4/GPR120 differs from that of other fatty acids.
    Nagasawa T; Horitani M; Kawaguchi SI; Higashiyama S; Hama Y; Mitsutake S
    FEBS Open Bio; 2021 Nov; 11(11):3081-3089. PubMed ID: 34535977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Selectivity Study of FFAR4/FFAR1 Agonists by Molecular Modeling.
    Zhang X; Sun H; Wen X; Yuan H
    J Chem Inf Model; 2019 Oct; 59(10):4467-4474. PubMed ID: 31580060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel identification approach for discovery of 5-HydroxyTriptamine 2A antagonists: combination of 2D/3D similarity screening, molecular docking and molecular dynamics.
    Kumar R; Jade D; Gupta D
    J Biomol Struct Dyn; 2019 Mar; 37(4):931-943. PubMed ID: 29468945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular docking and molecular dynamics simulation studies of GPR40 receptor-agonist interactions.
    Lu SY; Jiang YJ; Lv J; Wu TX; Yu QS; Zhu WL
    J Mol Graph Model; 2010 Jun; 28(8):766-74. PubMed ID: 20227312
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of potential dual agonists of FXR and TGR5 using e-pharmacophore based virtual screening.
    Sindhu T; Srinivasan P
    Mol Biosyst; 2015 May; 11(5):1305-18. PubMed ID: 25787676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Machine Learning Approach for the Discovery of Ligand-Specific Functional Mechanisms of GPCRs.
    Plante A; Shore DM; Morra G; Khelashvili G; Weinstein H
    Molecules; 2019 Jun; 24(11):. PubMed ID: 31159491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Approaches for Differentiation and Interconverting GPCR Agonists and Antagonists.
    Miszta P; Jakowiecki J; Rutkowska E; Turant M; Latek D; Filipek S
    Methods Mol Biol; 2018; 1705():265-296. PubMed ID: 29188567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular screening of glycyrrhizin-based inhibitors against ACE2 host receptor of SARS-CoV-2.
    Ahmad S; Waheed Y; Abro A; Abbasi SW; Ismail S
    J Mol Model; 2021 Jun; 27(7):206. PubMed ID: 34169390
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aberrant fatty acid profile and FFAR4 signaling confer endocrine resistance in breast cancer.
    Chu X; Zhou Q; Xu Y; Jiang J; Li Q; Zhou Q; Wu Q; Jin M; Wang H; Gu Y; Wang X; Wang B; He S; He X; Wu C; Zhang F; Zhang Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):100. PubMed ID: 30795784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of novel G-protein-coupled receptor 40 (GPR40) agonists by hybrid
    Nath V; Ahuja R; Kumar V
    J Biomol Struct Dyn; 2019 Sep; 37(14):3764-3787. PubMed ID: 30252605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of hydrophobic and hydrogen bonding interactions on the potency of ß-alanine analogs of G-protein coupled glucagon receptor inhibitors.
    Venugopal PP; Das BK; Soorya E; Chakraborty D
    Proteins; 2020 Feb; 88(2):327-344. PubMed ID: 31443129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Developing Hispolon-based novel anticancer therapeutics against human (NF-κβ) using
    Paul M; Kumar Panda M; Thatoi H
    J Biomol Struct Dyn; 2019 Sep; 37(15):3947-3967. PubMed ID: 30295165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular interaction fingerprint approaches for GPCR drug discovery.
    Vass M; Kooistra AJ; Ritschel T; Leurs R; de Esch IJ; de Graaf C
    Curr Opin Pharmacol; 2016 Oct; 30():59-68. PubMed ID: 27479316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of the Binding Affinities and Selectivity for CB1 and CB2 Ligands Using Homology Modeling, Molecular Docking, Molecular Dynamics Simulations, and MM-PBSA Binding Free Energy Calculations.
    Ji B; Liu S; He X; Man VH; Xie XQ; Wang J
    ACS Chem Neurosci; 2020 Apr; 11(8):1139-1158. PubMed ID: 32196303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting protein tyrosine phosphatase to unravel possible inhibitors for Streptococcus pneumoniae using molecular docking, molecular dynamics simulations coupled with free energy calculations.
    Zaman Z; Khan S; Nouroz F; Farooq U; Urooj A
    Life Sci; 2021 Jan; 264():118621. PubMed ID: 33164832
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 M
    Mohan A; Rendine N; Mohammed MKS; Jeeva A; Ji HF; Talluri VR
    Mol Divers; 2022 Jun; 26(3):1645-1661. PubMed ID: 34480682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Self-docking and cross-docking simulations of G protein-coupled receptor-ligand complexes: Impact of ligand type and receptor activation state.
    Thomas BN; Parrill AL; Baker DL
    J Mol Graph Model; 2022 May; 112():108119. PubMed ID: 34979368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.